Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection

被引:51
作者
George G. Zhanel
机构
[1] University of Manitoba,Faculties of Medicine and Pharmacy
[2] Health Sciences Centre,Departments of Medicine and Microbiology
关键词
Levofloxacin; Streptococcus Pneumoniae; Lactam; Antimicrob Agent; Gatifloxacin;
D O I
10.1007/s11908-001-0056-x
中图分类号
学科分类号
摘要
When evaluating the efficacy of antibiotics for the treatment of respiratory tract infections, such as community acquired pneumonia and acute exacerbations of chronic bronchitis, assessment of clinical cure may not be the most relevant parameter, as it may not be related to microbiological eradication or to the minimum inhibitory concentration (MIC) of the infecting pathogen. It is more relevant to study the efficacy of the antibiotic in eradicating the bacterial pathogen, because this is frequently related to both the MIC of the pathogen and the antibiotic dosage regimen. Pharmacodynamics correlates the concentration of antibiotic in the blood or at the infection site with its biological effect against the organism (bacteriological eradication). For β-lactams, the pharmacodynamic parameter that best correlates with eradication is time (T) above MIC (T > MIC); for aminoglycosides and fluoroquinolones, it is the area under the curve at 24 hours (AUC24)-to-MIC ratio (AUC24/MIC). Knowledge of pharmacodynamics allows optimum use of antibiotics; in vitro models, animal models, and retrospective and prospective clinical trials have shown that the use of such knowledge optimizes bacteriological eradication and enhances patient outcome. In the future, pharmacodynamic studies will be used not only to assess optimal ways for antibiotics to eradicate resistant pathogens, but also to investigate the ability of antibiotics to prevent the development of resistance on therapy and to eradicate pathogens from colonizing sites.
引用
收藏
页码:29 / 34
页数:5
相关论文
共 80 条
[1]  
Hoban DJ(1999)Antibiotic resistance in respiratory tract pathogens Can Respir J 6 27A-30A
[2]  
Karlowsky JA(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-12
[3]  
Zhanel GG(1994)Pharmacokinetic contributions to postantibiotic effects: focus on aminoglycosides Clin Pharmacokinet 24 377-392
[4]  
Craig W(1998)Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials JAMA 279 125-129
[5]  
Zhanel GG(1996)Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr Infect Dis J 15 944-948
[6]  
Craig WA(1999)Pharmacokinetics and pharmacodynamics of fluoroquinolones Drugs 58 29-36
[7]  
Preston SL(2000)Pharmacodynamics to combat antibiotic resistance J Antimicrob Chemother 46 25-31
[8]  
Drusan GL(1999)Pharmacodynamic principles of antibiotic therapy and the prevention of resistance Chest 115 19S-23S
[9]  
Berman AL(1997)Efficacy of β-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics Diagn Microbiol Infect Dis 27 29-33
[10]  
Craig WA(1995)The importance of pharmacokinetics/pharmacodynamics surrogate markers to outcome: focus on antibacterial agents Clin Pharmacokinet 28 143-160